These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 22574676)

  • 41. Animal models of alcoholism: neurobiology of high alcohol-drinking behavior in rodents.
    McBride WJ; Li TK
    Crit Rev Neurobiol; 1998; 12(4):339-69. PubMed ID: 10348615
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sazetidine-A, a novel ligand that desensitizes alpha4beta2 nicotinic acetylcholine receptors without activating them.
    Xiao Y; Fan H; Musachio JL; Wei ZL; Chellappan SK; Kozikowski AP; Kellar KJ
    Mol Pharmacol; 2006 Oct; 70(4):1454-60. PubMed ID: 16857741
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Review of topiramate: an antiepileptic for the treatment of alcohol dependence.
    Kenna GA; Lomastro TL; Schiesl A; Leggio L; Swift RM
    Curr Drug Abuse Rev; 2009 May; 2(2):135-42. PubMed ID: 19630744
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Turning the clock ahead: potential preclinical and clinical neuropharmacological targets for alcohol dependence.
    Leggio L; Cardone S; Ferrulli A; Kenna GA; Diana M; Swift RM; Addolorato G
    Curr Pharm Des; 2010; 16(19):2159-18. PubMed ID: 20482506
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Histamine H3 receptor antagonist decreases cue-induced alcohol reinstatement in mice.
    Nuutinen S; Mäki T; Rozov S; Bäckström P; Hyytiä P; Piepponen P; Panula P
    Neuropharmacology; 2016 Jul; 106():156-63. PubMed ID: 26107118
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Physicians' opinions about medications to treat alcoholism.
    Mark TL; Kranzler HR; Song X; Bransberger P; Poole VH; Crosse S
    Addiction; 2003 May; 98(5):617-26. PubMed ID: 12751979
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acamprosate for the treatment of alcohol dependence.
    Boothby LA; Doering PL
    Clin Ther; 2005 Jun; 27(6):695-714. PubMed ID: 16117977
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Acamprosate--a novel treatment for alcoholism].
    Golovko SI; Zefirov SIu; Golovko AI; Shpilenia LS; Nekrasov IuA
    Eksp Klin Farmakol; 2000; 63(3):70-3. PubMed ID: 10934602
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Meta-analysis of pharmacological therapy with acamprosate, naltrexone, and disulfiram--a systematic review].
    Petrov I; Krogh J; Nordentoft M
    Ugeskr Laeger; 2011 Nov; 173(48):3103-9. PubMed ID: 22118653
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New pharmacological approaches for the treatment of alcoholism.
    Soyka M; Roesner S
    Expert Opin Pharmacother; 2006 Dec; 7(17):2341-53. PubMed ID: 17109610
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Suppression of alcohol preference in high alcohol drinking rats: efficacy of amperozide versus naltrexone.
    Myers RD; Lankford MF
    Neuropsychopharmacology; 1996 Feb; 14(2):139-49. PubMed ID: 8822536
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A selective ALDH-2 inhibitor reduces anxiety in rats.
    Overstreet DH; Knapp DJ; Breese GR; Diamond I
    Pharmacol Biochem Behav; 2009 Dec; 94(2):255-61. PubMed ID: 19747934
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The metabotropic glutamate 5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine reduces ethanol self-administration in multiple strains of alcohol-preferring rats and regulates olfactory glutamatergic systems.
    Cowen MS; Djouma E; Lawrence AJ
    J Pharmacol Exp Ther; 2005 Nov; 315(2):590-600. PubMed ID: 16014750
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A translational approach to novel medication development for protracted abstinence.
    Mason BJ; Higley AE
    Curr Top Behav Neurosci; 2013; 13():647-70. PubMed ID: 22351425
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of the combination of naltrexone and acamprosate on alcohol intake in mice.
    Kim SG; Han BD; Park JM; Kim MJ; Stromberg MF
    Psychiatry Clin Neurosci; 2004 Feb; 58(1):30-6. PubMed ID: 14678454
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acamprosate: recent findings and future research directions.
    Mann K; Kiefer F; Spanagel R; Littleton J
    Alcohol Clin Exp Res; 2008 Jul; 32(7):1105-10. PubMed ID: 18540918
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Does family history of alcoholism moderate naltrexone's effects on alcohol use?
    Capone C; Kahler CW; Swift RM; O'Malley SS
    J Stud Alcohol Drugs; 2011 Jan; 72(1):135-40. PubMed ID: 21138720
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Evaluation of drug treatment of primary alcoholism].
    Rueff B
    Rev Prat; 1999 Feb; 49(4):400-2. PubMed ID: 10319691
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Advances in development of medications for alcoholism treatment.
    Litten RZ; Allen JP
    Psychopharmacology (Berl); 1998 Sep; 139(1-2):20-33. PubMed ID: 9768539
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potential neuroprotective effects of acamprosate.
    Koob GF; Mason BJ; De Witte P; Littleton J; Siggins GR
    Alcohol Clin Exp Res; 2002 Apr; 26(4):586-92. PubMed ID: 11981137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.